Dunno Pharmaceutical-B (06872) will be accepting IPO applications from May 14th to May 19th, and is expected to be listed on May 22nd.

Danno Pharmaceuticals-B (06872) will be listed from May 14 to May 19, 2026. The company plans to globally issue 8.28055 million shares, with 10% of the shares being offered in Hong Kong and 90% internationally. The offering price will be HK$75.70 per share and trading is expected to commence on the Stock Exchange on May 22, 2026. The company was incorporated in 2013 and is a biotechnology company near commercialization, focusing on discovering, developing, and commercializing innovative drug products to address unmet clinical needs in the areas of bacterial infections and bacterial metabolism related diseases. As of the latest practicable date, the company has established a pipeline consisting of seven innovative projects, including two core products: TNP-2198, a new molecular entity (NME) candidate drug to be used in China and the United States as part of triple therapy with amoxicillin and PPI for the treatment of Helicobacter pylori infection, and as a single therapy for the treatment of bacterial vaginosis and difficult C. difficile infection; and TNP-2092 injection, a triple-targeted therapy for implant-related bacterial infections (such as acute bacterial skin and skin structure infections (ABSSSI) and prosthetic joint infections (PJI) in China and the United States, for the treatment of left ventricular assist device infections (LVADI) and central venous catheter-related bloodstream infections (CRBSI)). The company has entered into cornerstone investment agreements, pursuant to which cornerstone investors (AMR Action Fund, L.P, AMR Action Fund, SCSp, Hillhouse Management Consultancy (Hong Kong) Limited, Oriental Asset Management (Hong Kong) Limited, and Junying Global Limited) have agreed (subject to certain conditions) to subscribe for a total of US$29.8 million (approximately HK$233.5 million) worth of shares at the offering price. Based on the offering price of HK$75.70 per share, the total number of shares to be subscribed by cornerstone investors will be 3.0844 million shares. Assuming that the overallotment option and the additional share placement option are not exercised and based on an offering price of HK$75.70 per share, the company estimates that the net proceeds from the global offering will be approximately HK$557.8 million. The company plans to use the net proceeds from the global offering for the following purposes: 71.0% for the research, development, registration filing, and commercialization of the company's core products; 7.0% to fund the research and development of TNP-2092 oral formulation; 7.3% for the research and development of the company's other candidate products; 7.2% for the construction of the company's own factory; and 7.5% for working capital and other general corporate purposes.